Headache

Domo Boosts Flexible Data Foundation with Robust Enhancements to Cloud Amplifier

Retrieved on: 
Thursday, March 28, 2024
Technology, Security, Professional Services, Software, Networks, Internet, Data Analytics, Data Management, Artificial Intelligence, Cloud, Conference, Headache, EVP, BigQuery, AI, Cloud analytics, Business intelligence, Extract, Analysis, MySQL, Cloud computing, Video game

Today Domo (Nasdaq: DOMO) announced at Domopalooza: the AI + Data Conference enhancements to Cloud Amplifier, the company’s multi-cloud data offering, to enable users with the powerful and flexible tools they need to fully integrate with multiple cloud data platforms and deliver actionable AI-driven insights while maintaining the security and governance organizations need.

Key Points: 
  • Today Domo (Nasdaq: DOMO) announced at Domopalooza: the AI + Data Conference enhancements to Cloud Amplifier, the company’s multi-cloud data offering, to enable users with the powerful and flexible tools they need to fully integrate with multiple cloud data platforms and deliver actionable AI-driven insights while maintaining the security and governance organizations need.
  • “Millions of users across these cloud platforms no longer need to pull data out of their native systems to transform, clean and derive value from their data.
  • Given that cloud costs are a key consideration for any modern business, these new Cloud Amplifier settings allow you to control how often Domo communicates with your data cloud, ensuring data meets the needs of the user or organization but is managed in an efficient way to avoid unnecessary costs.
  • For more information on Domo Cloud Amplifier, visit: www.domo.com/platform/leverage-the-cloud

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Tuesday, March 26, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Microangiopathic hemolytic anemia, Incidence, Headache, Patient, Thrombotic thrombocytopenic purpura, Constipation, Mortality, Head, TTP, Nausea, Toll, Heart, Safety, Itch, Thrombocytopenia, Hypertension, Pharmaceutical industry

Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.

Key Points: 
  • Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
  • cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.2 It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura (TTP) manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.2,3,4 When left untreated, acute TTP events have a mortality rate of >90%.2,4
    “The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition,” said Yasushi Kajii, Head, R&D Japan Region at Takeda.
  • “Developing innovative treatments that make a difference in the lives of patients is at the heart of what we do.
  • In Period 3, the incidence of TEAEs was 2.8% (1/36) in this drug group: nausea and headache (1 subject each).6
    This approval does not result in any changes to Takeda’s consolidated forecast for the fiscal year ending March 31, 2024 (FY2023).

Global Balloon Catheter Market Analysis Report 2023-2030: Minimally Invasive Solutions and Age-Associated Cardiovascular Problems Drive Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, Coronary artery disease, Balloon catheter, Neurology, Prevalence, Headache, Urbanization, Blood, Peripheral artery disease, Urology, Angioplasty, Nylon, Hospital, Restenosis, Research, Splenic infarction, Telehealth, Heart, Stroke, Artery, Safety, Prognosis, Catheter, FDA, Artificial intelligence, CAD, Ageing, Medical device

The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of age-associated cardiovascular problems propels balloon catheter demand, significantly increasing the medical device market and enhancing the care of growing older populations globally.
  • Offering minimally invasive alternatives to conventional surgeries, balloon catheters lead to faster recuperation instances, decreased dangers, and progressed patient effects, driving market increase towards minimally invasive tactics.
  • By product type, the Global Balloon Catheter Market is divided into Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, Scoring Balloon Catheter, Stent Graft Balloon Catheter, and Others.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

DataGrail’s AI Governance Solution Uncovers Shadow AI & Helps Businesses Innovate with Confidence

Retrieved on: 
Wednesday, March 13, 2024
Apps, Applications, Technology, Mobile, Wireless, Security, Software, Networks, Internet, Data Management, Artificial Intelligence, Microsoft, EEG, Organization, Software as a service, OpenAI, University, Headache, Data mining, Risk, Salesforce, CO, Policy, Classification, AI, PIAS, Overture, Risk assessment, Publication, Data, Yahoo!, Machine learning, Multimedia, Privacy, Medical device

At a time when 48% of CISOs cite AI security as their biggest concern, DataGrail’s AI Governance Solution uncovers AI risks in third-party apps and systems that power their business, helping organizations get the benefits of AI innovation, while understanding and managing its associated risks.

Key Points: 
  • At a time when 48% of CISOs cite AI security as their biggest concern, DataGrail’s AI Governance Solution uncovers AI risks in third-party apps and systems that power their business, helping organizations get the benefits of AI innovation, while understanding and managing its associated risks.
  • View the full release here: https://www.businesswire.com/news/home/20240313437294/en/
    DataGrail’s AI Governance Solution uncovers AI risks in third-party apps and systems that power their business, helping organizations get the benefits of AI innovation, while understanding and managing its associated risks.
  • Available to enterprises and consumer brands, DataGrail provides a framework for businesses to develop their own customized AI principles and policy based on their values.
  • With DataGrail’s AI Governance Solution security and privacy teams can:
    Discover traditional AI and generative AI models in third parties: DataGrail’s Responsible Data Discovery continuously detects AI and generative AI models used throughout an organization's SaaS and third-party systems.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Azul Reports Accelerated Growth Across Product Lines and Geographies, Boosted by Oracle’s Java Pricing Change and Rising Cloud Costs

Retrieved on: 
Tuesday, March 12, 2024
Data Management, Technology, Mobile, Wireless, Software, Networks, Internet, Cloud, Graviton, Consultant, Uncertainty, University of Sydney, ARR, Growth, University, Headache, Policy, ARM, AWS, Java Platform, Standard Edition, Cisco, Investment, Crac, Oracle, AWS Graviton, Intelligence, Cloud computing, Core, OpenJDK, Video game

Azul , the only company 100% focused on Java, today announced accelerated growth last year across its product portfolio and geographies, including unprecedented demand for its OpenJDK products in the wake of Oracle’s Java SE pricing policy change and enterprises grappling with soaring cloud costs.

Key Points: 
  • Azul , the only company 100% focused on Java, today announced accelerated growth last year across its product portfolio and geographies, including unprecedented demand for its OpenJDK products in the wake of Oracle’s Java SE pricing policy change and enterprises grappling with soaring cloud costs.
  • Since that announcement, Azul has seen tremendous growth in new customer bookings for its OpenJDK-based Oracle alternative, Azul Platform Core , with an increase of 49% year-over-year.
  • One customer, the University of Sydney, switched from Oracle Java to Azul Platform Core, looking for cost savings, greater predictability and ease of doing business.
  • Reinforcing its leadership in Java, Azul was also re-elected to the Java Committee Executive Team, a key steering committee for Java, its development and roadmap.

Windstream Enterprise Debuts Secure Flex Premium with Fortinet for Maximum Enterprise Agility and Digital Acceleration

Retrieved on: 
Monday, March 11, 2024
Telecommunications, Software, Networks, Internet, Data Management, Technology, Mobile, Wireless, Security, ZTNA, Headache, Environment, EPP, Health, Windstream Holdings, Risk, Seamless, Secure access service edge, CISO, Policy, AI, Ecosystem, Posture, Risk management

What’s more, these larger businesses are struggling to stitch together disparate point solutions, which leads to increased complexity and vulnerability within an enterprise’s digital environment.

Key Points: 
  • What’s more, these larger businesses are struggling to stitch together disparate point solutions, which leads to increased complexity and vulnerability within an enterprise’s digital environment.
  • Delivered by Windstream Enterprise’s IT Managed Services team, Secure Flex Premium leverages Fortinet’s unique AI-powered cybersecurity platform, the Fortinet Security Fabric, and Fortinet’s secure networking solutions to enable clients to meet these business-critical demands, accelerate digital transformation initiatives, and provide complete visibility and control into their unique IT landscape.
  • Dedicated single-tenant solution: Secure Flex Premium is designed exclusively for each client to ensure a higher degree of control and customization over their entire IT environment.
  • With Windstream Enterprise as the managed services provider, enterprises remove the challenges and risk of managing disjointed point solutions from multiple vendors.

Lindus Health Partners with Amendola for PR Program to Promote Groundbreaking Model that Streamlines End-to-End Clinical Trials for Life Sciences

Retrieved on: 
Thursday, April 4, 2024
ChromeOS, Research, Headache, Running, AI

Amendola is implementing a comprehensive PR plan to demonstrate Lindus Health's industry-leading technology and services, accomplishments, customer wins, and industry partnerships.

Key Points: 
  • Amendola is implementing a comprehensive PR plan to demonstrate Lindus Health's industry-leading technology and services, accomplishments, customer wins, and industry partnerships.
  • "We are thrilled to work with Amendola to demonstrate to the market how Lindus Health's new model offers more rapid, high-quality clinical trials together with transparent pricing."
  • The company is passionate about using the highest-quality scientific methods available and homegrown cutting-edge technology, including AI, to conduct radically faster, more reliable clinical trials.
  • "Lindus Health is poised to transform how clinical trials are executed and we look forward to raising awareness across the industry."

NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine

Retrieved on: 
Thursday, April 4, 2024
Neurology, University, Vii, Disability, Sound, Pfizer, CGRP, Headache, Migraine, Ageing, Light, Health Canada, Nausea, Myenteric plexus

KIRKLAND, QC, April 4, 2024 /CNW/ - NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.iii NURTEC is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist tablet.

Key Points: 
  • KIRKLAND, QC, April 4, 2024 /CNW/ - NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.iii NURTEC is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist tablet.
  • "It is an exciting time for Canadians to now have another targeted, migraine specific therapy in their management toolbox."
  • People living with migraine are looking for timely and equitable access to new options to effectively manage this highly debilitating disease," said Wendy Gerhart from Migraine Canada.
  • "Pfizer Canada is proud to bring this new therapy to Canadians impacted by migraine," said Andréa Mueller, Primary Care Portfolio Lead, Pfizer Canada.